Marinus Pharmaceuticals (MRNS) : Traders are bullish on Marinus Pharmaceuticals (MRNS) as it has outperformed the S&P 500 by a wide margin of 29.48% in the past 4 weeks. The bullishness in the stock continues even in the near-term as the stock has returned an impressive 37.8%, relative to the S&P 500. The stock has continued its bullish performance both in the near-term and the medium-term, as the stock is up 39.86% in the last 1 week, and is up 35.14% in the past 4 weeks. Buying continues as the stock moves higher, suggesting a strong appetite for the stock. The stock has recorded a 20-day Moving Average of 39.59% and the 50-Day Moving Average is 42.12%.
Marinus Pharmaceuticals (NASDAQ:MRNS): During Fridays trading session, Bulls were in full control of the stock right from the opening. The stock opened at $1.84 and $1.75 proved to be the low of the day. Continuous buying at higher levels pushed the stock towards an intraday high of $2.23. The buying momentum continued till the end and the stock did not give up its gains. It closed at $2.00, notching a gain of 12.36% for the day. The total traded volume was 3,702,849 . The stock had closed at $1.78 on the previous day.
The company Insiders own 5% of Marinus Pharmaceuticals shares according to the proxy statements. Institutional Investors own 50.04% of Marinus Pharmaceuticals shares. In a related news, Cashman Christopher Michael, CEO of Marinus Pharmaceuticals Inc, executed a transaction worth $19,977 on November 6, 2015. A total of 3,561 shares were purchased at an average price of $5.61. The Insider information was divulged by the Securities and Exchange Commission in a Form 4 filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Marinus Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company. The Company focuses on developing and commercializing neuropsychiatric therapeutics. Its clinical stage product candidate, ganaxolone, is a small molecule that is a synthetic analog of allopregnanolone, which is an endogenous neurosteriod known for its anticonvulsive and antianxiety activity. Ganaxolone was rationally designed to unlock the potential for chronic neurosteroid therapy through modulation of the GABAA receptor. The Companys indication for ganaxolone is as an adjunctive, or add-on, therapy for the treatment of partial, also known as focal, onset seizures in adults with epilepsy. Phase III randomized multinational clinical trial by utilizing the Companys oral capsules. The Company has completed a Phase II clinical trial in 147 patients with focal onset seizures.